NCT05236036View on ClinicalTrials.gov

Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

February 10, 2027

Study Completion Date

January 3, 2029

Conditions
AstrocytomaGlioblastomaGlioblastoma, IDH-WildtypeMGMT-Unmethylated GlioblastomaRecurrent Glioblastoma
Interventions
DRUG

Mycophenolate Mofetil

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

RADIATION

Radiation Therapy

Receive radiation therapy

DRUG

Temozolomide

Given Orally (PO)

Trial Locations (1)

60611

RECRUITING

Northwestern University, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Northwestern University

OTHER